These findings collectively suggest that SHYZD may enhance learning and memory abilities in AD by modulating the NF-κB/NLRP3 pathway to inhibit inflammasome activation and mitigate the neuroinflammatory response. Here, NFKB1 is linked to Alzheimer disease.